A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine TumorsSandip Pravin Patel, Razelle Kurzrock, Jourdain Hayward et al.|Clinical Cancer Research|2020Cited by 326
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Razelle Kurzrock, Edward Mayerson, Rashmi Chugh et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 159
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107Przemyslaw Twardowski, Primo N. Lara, Shu Tao et al.|Kidney Cancer|2017Cited by 41